Humira and Skin hyperpigmentation - a phase IV clinical study of FDA data

Summary:

Skin hyperpigmentation is reported as a side effect among people who take Humira (adalimumab), especially for people who are female, 50-59 old, have been taking the drug for 5 - 10 years also take Methotrexate, and have Psoriasis.

The phase IV clinical study analyzes which people have Skin hyperpigmentation when taking Humira. It is created by eHealthMe based on reports of 758,421 people who have side effects when taking Humira from the FDA, and is updated regularly.

What is Humira?

Humira has active ingredients of adalimumab. It is often used in rheumatoid arthritis. eHealthMe is studying from 761,396 Humira users. Check the latest studies of Humira.

What is Skin hyperpigmentation?

Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 646 drugs and 811 conditions by eHealthMe. Check the latest studies of Skin hyperpigmentation.

On Jul, 15, 2026

758,421 people reported to have side effects when taking Humira.
Among them, 72 people (0.01%) have Skin hyperpigmentation.

Could Humira cause Skin hyperpigmentation?

Among these 72 people:

How long have people been on Humira when they have Skin hyperpigmentation? *

What is the gender of people who have Skin hyperpigmentation when taking Humira? *

female: 70.42 %
male: 29.58 %

What is the age of people who have Skin hyperpigmentation when taking Humira? *

What are other drugs people take besides Humira? *

What are other side effects people have besides Skin hyperpigmentation? *

Rashes (redness): 20 people, 27.78%
Rash Macular (small, flat red spots): 14 people, 19.44%
Joint Pain: 14 people, 19.44%
Itching: 14 people, 19.44%
Psoriasis (immune-mediated disease that affects the skin): 13 people, 18.06%
Pain In Extremity: 11 people, 15.28%
Gait Disturbance: 9 people, 12.50%
Skin Exfoliation (removal of the oldest dead skin cells): 9 people, 12.50%
Macule (a discoloured spot on the skin): 9 people, 12.50%
Oedema Peripheral (superficial swelling): 9 people, 12.50%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 25 people, 34.72%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 10 people, 13.89%
Ankylosing Spondylitis (type of arthritis affecting the spine): 4 people, 5.56%
Arthropathy: 3 people, 4.17%
High Blood Pressure: 3 people, 4.17%
Hidradenitis (chronic disease of a type of sweat gland): 2 people, 2.78%
Diabetes: 2 people, 2.78%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 1.39%
Asthma: 1 person, 1.39%
Fluid Retention (an abnormal accumulation of fluid in the blood): 1 person, 1.39%

* Approximation only. Some reports may have incomplete information.

Do you take Humira and have Skin hyperpigmentation?

- Check whether Skin hyperpigmentation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Humira:

Humira (761,396 reports)

Browse all side effects of Humira:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (646 drugs)

Browse all the conditions that are associated with Skin hyperpigmentation:

Skin hyperpigmentation (811 conditions)

Related publications that referenced our studies

Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on adalimumab (the active ingredients of Humira) and Humira (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.